Skip to content

Concordance Between Inflammatory Activity Assessed by Enteric MRI With and Without Intestinal Distension Product in Patients With Ileal Crohn's Disease.

Study of Concordance Between Inflammatory Activity Assessed by Enteric MRI With and Without Intestinal Distension Product in Patients With Ileal Crohn's Disease.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07471438
Acronym
CONFORT
Enrollment
60
Registered
2026-03-13
Start date
2026-04-22
Completion date
2026-09-01
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease (CD)

Keywords

Crohn Disease, MRI

Brief summary

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that can significantly impair patients' quality of life. Due to its transmural nature (affecting the entire thickness of the intestinal wall), it naturally progresses to intestinal destruction (stenosis, fistula), requiring intestinal resection in approximately half of patients during follow-up. The long-term goal for patients is to maintain a normal life, i.e., without symptoms and without intestinal destruction. To this end, short- and medium-term therapeutic goals have evolved in recent years. Clinical remission is not a sufficient goal, as it has not changed the natural history of the disease. The current goal is to achieve a combination of clinical remission and endoscopic mucosal healing, as this is associated with a reduced risk of adverse outcomes (recurrence of symptoms, hospitalization, intestinal resection). Transmural healing assessed by MRI is also a promising goal associated with a reduced risk of adverse outcomes (recurrence of symptoms, hospitalization, intestinal resection). Furthermore, it is associated with a lower risk of progression to intestinal destruction, unlike endoscopic remission. In this context, transmural healing could soon become the benchmark in terms of therapeutic objectives for Crohn's disease, particularly in the ileum. Although enteric MRI is better accepted than colonoscopy by patients with Crohn's disease, in the ACCEPT1 study, nearly half of patients (48.6%) reported the need to use an intestinal distension product (PEG, mannitol, etc.) as a significant obstacle to repeating entero-MRI, while more than a third complained of vomiting (33.7%) or severe diarrhea (35.0%) induced by these same products. Being able to do without the use of distension products would significantly improve the acceptability of entero-MRI. The investigators hypothesize that an enteric MRI without distension would lead to poorer ileal distension but would allow inflammatory activity scores to be assessed on MRI in a manner similar to an examination with distension, and thus would not impact the need for therapeutic intensification.

Detailed description

This is a prospective, multicenter (5 centers), cross-sectional concordance study including adult patients with ileal and/or colonic Crohn's disease requiring MR enterography for reassessment of disease activity. Patients will undergo two MR enterography scans at 2 and 7 days intervals. The first scan will be performed without a distension agent, and the second with intestinal distension (as is standard practice). A gadolinium-based contrast agent will be used in both MR enterography scans. Furthermore, the MRI protocols and sequences will be identical. The images will be anonymized and uploaded to a dedicated platform for centralized review by two expert radiologists (randomly selected) blinded to clinical data. The primary endpoint will be the C-score (a quantitative variable), the concordance of which will be assessed using Lin's coefficient.

Interventions

PROCEDUREMRI

All patients included in the study will undergo an MRI without contrast medium in order to compare the inflammatory damage visible on an MRI with contrast agent.

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Investigator)

Intervention model description

All patients will have two MRI scans one week apart, one with and one without contrast agent.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with Crohn's disease according to European recommendations (ECCO) ≥ 18 years of age * With known or suspected ileal ± colonic involvement * Requiring reassessment of disease inflammatory activity according to the clinician * Able to give informed consent to participate in the research. * Affiliation with a Social Security scheme * Agreeing to undergo two MRIs in the same week

Exclusion criteria

* Isolated colonic Crohn's disease * Resection \> 1 m of small intestine * Severe obstructive symptoms defined according to CDOS (Crohn's disease obstructive symptoms score) * Uncontrolled intra-abdominal abscess * Isolated anoperineal lesions * Prevention of postoperative endoscopic recurrence * Temporary or permanent stoma * Total colectomy * Contraindication to MRI * Pregnant or breastfeeding women * Protected adults (under guardianship, trusteeship, family authorization, future protection mandate, with representation relating to the person)

Design outcomes

Primary

MeasureTime frameDescription
Modified Clermont score (C-Score)From enrollement to the end of the follow up at 7th dayquantitative variable, whose concordance will be assessed by Lin's coefficient.

Secondary

MeasureTime frameDescription
MaRIA scoreFrom enrollement to the end of the follow up at 7th dayquantitative variable, whose concordance will be assessed by Lin's coefficient
Transmural inflammatory activityFrom enrollement to the end of the follow up at 7th daydefined by a C-score \> 0.5, binary variable, whose concordance will be assessed by the kappa coefficient
Numerical acceptability scaleFrom enrollement to the end of the follow up at 7th dayNumerical acceptability scale from 0 to 10 (10 = perfect acceptability)
Numerical scale for intestinal distensionFrom enrollement to the end of the follow up at 7th dayNumerical scale from 0 to 10 (10 = perfect acceptability)
Likert scale for intestinal distension qualityFrom enrollement to the end of the follow up at 7th day(0 = very poor, 1 = poor, 2 = fair distension, 3 = good distension, and 4 = excellent distension)
Percentage of side effects of interest within 48 hours of the examinationAfter each MRI(diarrhea, fecal urgency, change in stool consistency, vomiting, nausea)

Countries

France

Contacts

CONTACTLise Laclautre
promo_interne_drci@chu-clermontferrand.fr+33473754963
PRINCIPAL_INVESTIGATORAnthony BUISSON, Professor

cl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026